Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody
about
How I treat paroxysmal nocturnal hemoglobinuriaFormation and functional significance of a molecular complex derived from the second and the fourth component of human complementCharacterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes.Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. II. The role of complement components in the increased sensitivity of PNH red cells to immune lysisDetection of complement components on unlysed erythrocytes from acid hemolysis and thrombin test reactions in paroxysmal nocturnal hemoglobinuria.Paroxysmal nocturnal hemoglobinuria--present status and future prospects.Historical aspects of paroxysmal nocturnal haemoglobinuria: 'defining the disease'.Dr(a-) polymorphism of decay accelerating factor. Biochemical, functional, and molecular characterization and production of allele-specific transfectants.Fixation of the first component of complement (C'la) by human antibodies.Mechanisms of immune lysis of the red cells in hereditary erythroblastic multinuclearity with a positive acidified serum test and paroxysmal nocturnal hemoglobinuriaHemoglobinuria misidentified as hematuria: review of discolored urine and paroxysmal nocturnal hemoglobinuria.Studies on the in vivo effects of antibody. Interaction of IgM antibody and complement in the immune clearance and destruction of erythrocytes in man.Measurement of the third component of complement bound to red blood cells in patients with the cold agglutinin syndrome.Mechanisms of immune lysis of red blood cells in vitro. I. Paroxysmal nocturnal hemoglobinuria cells.Presence of the Tn antigen on hematopoietic progenitors from patients with the Tn syndromeInteractions of the platelets in paroxysmal nocturnal hemoglobinuria with complement. Relationship to defects in the regulation of complement and to platelet survival in vivo.Acute myeloblastic leukemia in paroxysmal nocturnal hemoglobinuria. Evidence of evolution from the abnormal paroxysmal nocturnal hemoglobinuria clone.Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuriaAbnormality of glycophorin-alpha on paroxysmal nocturnal hemoglobinuria erythrocytes.Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes.A platelet and granulocyte membrane defect in paroxysmal nocturnal hemoglobinuria: usefulness for the detection of platelet antibodies.Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytesA new aspect of the molecular pathogenesis of paroxysmal nocturnal hemoglobinuria.Complement-mediated haemolysis and the role of blood transfusion in paroxysmal nocturnal haemoglobinuria.Deficiency of lymphocyte function-associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria. Functional correlates and evidence for a phosphatidylinositol membrane anchor.Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAFParoxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemiaPotential link between MHC-self-peptide presentation and hematopoiesis; the analysis of HLA-DR expression in CD34-positive cells and self-peptide presentation repertoires of MHC molecules associated with paroxysmal nocturnal hemoglobinuria.Clonal expression of the Tn antigen in erythroid and granulocyte colonies and its application to determination of the clonality of the human megakaryocyte colony assay.Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.Rational engineering of a minimized immune inhibitor with unique triple-targeting properties.Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.Murine embryonic stem cells without pig-a gene activity are competent for hematopoiesis with the PNH phenotype but not for clonal expansion.The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab.Normal polymorphic variations and transcription of the decay accelerating factor gene in paroxysmal nocturnal hemoglobinuria cells.Enhanced complement-mediated lysis of type III paroxysmal nocturnal hemoglobinuria erythrocytes involves increased C9 binding and polymerization.Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going.Pathophysiology of common hemolytic syndromes.Quantitative immunology of immune hemolytic anemia. I. The fixation of C1 by autoimmune antibody and heterologous anti-IgG antibody.The significance of erythrocyte antigen site density. II. Hemolysis.
P2860
Q24648538-04500FA0-6874-4713-9DD7-2D5E72644BFCQ28610974-2DBE43D9-CC76-4579-A8E1-97514BB41C0FQ30449395-0EB062F0-792B-4628-8C11-2C0BDAC55447Q34081645-A5CC54F5-1DB7-49EC-BD92-4FC5DDA84441Q34081776-BD644CD9-87BA-40E8-8AAA-DC23BE7EE7AEQ34108063-F0EA7F38-8467-4224-BBC9-A35E3D9930B1Q34120817-362180B7-9925-418C-BBED-7FB2ACF30AE6Q34264494-0A437CF7-7117-4D2F-9C02-F90BBEB5D950Q34280156-AA656E78-1D25-4E92-8E5E-42E81384FB3DQ34458783-13E8EB44-6CC1-4B21-B04E-E3C224E00214Q34462881-31F98E01-8748-4B27-80E3-C95D03818740Q34464887-0C37D0E6-792C-470E-AED1-D35B5D2EEB84Q34499642-C7880C78-BE3D-49D3-B4B6-889ED8192622Q34503864-6CA1E940-8ECE-4EDF-88C7-99FF861A6FE2Q34530947-3D208B49-CD4E-4EEF-A7B8-6891D45791F7Q34554891-962FAC68-09BB-4716-82D9-EB01BB14160EQ34556908-5F0C0C3B-9CAD-43BF-B9E1-EA478C26DB1DQ34578218-C634846A-0B29-4293-862E-873C148FE228Q34608150-890FBFA3-7765-4E3B-960D-F9492C61240EQ35093962-9F620080-17AE-4A32-AD25-1DF134362633Q35571223-8CCC3A86-1F4C-4E08-8BEC-BFC4D00F014DQ35575831-1E68CC36-0DAF-4ED0-BFB6-5BF7C7837F9CQ35670980-82160FF8-B9F0-42DA-B43C-4094FD5D446BQ36187306-001E3F4B-42C4-43D2-9622-60EA7C651013Q36354062-07BD3A10-A8C2-4F30-8E09-8946DA0D3EC6Q36357616-76894C05-4DC5-46ED-84F2-C2E49DA64873Q36416292-916C1A41-3A62-4AD8-8FF5-1E7ACC8A3538Q36695249-EA6212BC-527D-4103-AD38-1E725901CF50Q36983013-9C637999-DEBD-432D-A19C-22F0323FD4AEQ37040534-01E02668-EA32-44AB-AE95-C78F93C2A4C7Q37300691-49C0B732-4F64-4B8D-B42C-366CA90CF653Q37346265-9C4DCD46-FA33-4453-BB16-59C7F656C02CQ37371566-2CAF7D6B-1455-48D9-8FD5-23D02256DA2AQ37462959-B68C7FE9-0AD0-422B-A923-0930062F292BQ37486381-FD6EC008-14BA-4EBE-8010-A0BA62DD41ADQ37547047-E6213ED2-818F-4010-A6B3-CF4938C407A6Q37724607-2477CCCB-284E-4116-8CE2-C394006C520CQ40004086-0A047212-95A3-4C72-B702-30993B46E03BQ40324632-AD120508-D0DB-4BF5-B50F-8E72BDD77BFEQ40325273-3F234E33-62FB-4B75-A29C-594B0FA3ECC7
P2860
Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody
description
1966 nî lūn-bûn
@nan
1966 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1966 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1966年の論文
@ja
1966年論文
@yue
1966年論文
@zh-hant
1966年論文
@zh-hk
1966年論文
@zh-mo
1966年論文
@zh-tw
1966年论文
@wuu
name
Immune lysis of normal human a ...... mplement and specific antibody
@ast
Immune lysis of normal human a ...... mplement and specific antibody
@en
type
label
Immune lysis of normal human a ...... mplement and specific antibody
@ast
Immune lysis of normal human a ...... mplement and specific antibody
@en
prefLabel
Immune lysis of normal human a ...... mplement and specific antibody
@ast
Immune lysis of normal human a ...... mplement and specific antibody
@en
P2860
P356
P1476
Immune lysis of normal human a ...... mplement and specific antibody
@en
P2093
P2860
P304
P356
10.1172/JCI105388
P407
P577
1966-05-01T00:00:00Z